Azitra, Inc. Announces Upcoming Reverse Stock Split on October 26, 2026

Azitra, Inc. Announces Upcoming Reverse Stock Split

Azitra, Inc., a clinical-stage biopharmaceutical company that is dedicated to advancing innovative therapies for precision dermatology, has unveiled its decision to implement a reverse stock split. This action is set to occur at a ratio of 1 post-split share for every 10 pre-split shares. The effective date for this reverse stock split is slated for October 26, 2026, at 12:01 AM Eastern Time.

The company's stock, which trades under the ticker symbol 'AZTR' on the NYSE American, will transition to a split-adjusted basis as trading resumes on October 26. Following this modification, the total number of issued shares will decrease significantly, going from approximately 60,603,742 shares to around 6,060,374 shares. This substantial reduction is part of a broader strategy that aims to improve the company's stock price and enhance its market position.

The decision for the reverse stock split comes after stockholders at the annual meeting on June 15, 2026, granted the Board of Directors the authority to enact such splits. The range authorized varied from 1-for-2 to 1-for-30, but ultimately the Board opted for a 1-for-10 ratio, which was formalized on October 14, 2026. This thoughtful approach demonstrates Azitra's strategy to maintain liquidity and fortify interest in its equity.

Shareholders holding stock via brokerage accounts will see their shares automatically adjusted to reflect the new split ratio. Interestingly, for any stockholders who have their shares in certificate form, there is no necessity to swap old certificates for new ones unless they choose to do so.

Importantly, the reverse stock split is designed to affect all shareholders evenly, preserving each individual's percentage interest in the company. However, any shareholder left with a fractional share as a result of the split will be compensated with cash. This will be calculated by determining the average closing prices of the stock on the NYSE American over the five trading days preceding the effective date.

The implications of this reverse stock split extend beyond simple share reallocation. It will also lead to proportional adjustments concerning the number of shares potential shareholders may receive through equity awards and warrants, along with any applicable exercise prices.

To obtain assistance or clarity about how this reverse stock split might affect their specific holdings, shareholders are advised to contact their brokers directly. Azitra's transfer agent, Continental Stock Transfer Trust Co., is also available for inquiries from stockholders of record.

For those seeking further information about the reverse stock split, a comprehensive overview can be found within Azitra's definitive proxy statement, which was filed with the Securities and Exchange Commission (SEC) on May 8, 2026. This document is accessible free of charge through the SEC's official website and Azitra’s company portal.

About Azitra, Inc.

Azitra, Inc. stands at the forefront of clinical-stage biopharmaceutical companies, emphasizing the growth and development of innovative treatments tailored for precision dermatology. Their research portfolio boasts significant products such as ATR-COSF, a recombinant protein technology aimed at cosmetics and skincare, and ATR-04, a promising investigational live biotherapeutic for managing rashes associated with EGFR inhibitors. The FDA has awarded Azitra a Fast Track designation for addressing EGFR inhibitor-associated rashes, which affect approximately 150,000 individuals in the United States alone.

In addition to these initiatives, Azitra is actively pursuing further advancements in recombinant protein technologies to enhance biotechnological research and manufacturing solutions. With a strong commitment to integrating engineered proteins, live biotherapeutics, advanced artificial intelligence, and a specialized microbial library, Azitra is dedicated to creating unique products that resonate across consumer, research, and healthcare landscapes. For more insightful details, the company invites interested parties to visit their official website at Azitra Inc.